20/20 BioLabs has entered an exclusive U.S. technology license and access agreement with ROKIT Healthcare to integrate ROKIT’s proprietary chronic kidney disease prediction algorithm into the 20/20 Longevity Platform, expanding the OneTest for Longevity biomarker-based risk assessment suite.
The agreement provides that ROKIT will reimburse 20/20 for one-third of the mutually agreed-upon sales and marketing expenses in exchange for a running royalty on the combined product’s net sales, and the parties anticipate negotiating a separate arrangement that could grant ROKIT exclusive commercialization rights for the longevity platform in Korea and potentially other East Asian markets.
The company claims clinical evidence suggests patients with lower systemic inflammation, measured by biomarkers such as CRP, tend to have more favorable biological responses to regenerative therapies, including ROKIT’s 3-D bio-printed tissue patches.
OneTest for Longevity launched in February 2026 and measures inflammatory biomarkers alongside OneTest for Cancer, the firm’s multi-cancer early detection test. According to the company, chronic kidney disease affects more than 35 million Americans. Tests are processed in a CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland.
